Melanin as a potential target for radionuclide therapy of metastatic melanoma

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

Bibliography

• 1  Safa MM, Foon KA: Adjuvant immunotherapy for melanoma and colorectal cancers. Semin. Oncol. 28(1), 68–92 (2001).
  Google Scholar
• 2  Sun W, Schuchter LM: Metastatic melanoma. Curr. Treat. Options Oncol.1, 193–202 (2001).Overview of currently available treatments for metastatic melanoma.
  MedlineGoogle Scholar
• 3  Cohen-Solal KA, Crespo-Carbone SM, Namkoong J et al.: Progressive appearance of pigmentation in amelanotic melanoma lesions. Pigment Cell Res.15(4), 282–289 (2002).
  Medline CASGoogle Scholar
• 4  Busam KJ, Hester K, Charles C et al.: Detection of clinically amelanotic malignant melanoma and assessment of its margins by in vivo confocal scanning laser microscopy. Arch. Dermatol.137(7), 923–929 (2001).
  Medline CASGoogle Scholar
• 5  Hearing V: The melanosome: the perfect model for cellular responses to the environment. Pigment Cell Res.13(Suppl. 8), 23–34 (2000).Detailed overview of melanosome development and its applicability to seeking new treatments for melanoma.
  MedlineGoogle Scholar
• 6  Wakamatsu K, Ito S: Advanced chemical methods in melanin determination. Pigment Cell Res.15, 174–183 (2002).Summarizes high performance liquid chromatography methods for determination of types of melanin in mammalian and other cell types.
  Medline CASGoogle Scholar
• 7  Srivastava SC, Dadachova E: Recent advances in radionuclide therapy. Semin. Nucl. Med. 31(4), 330–341 (2001).
  Medline CASGoogle Scholar
• 8  Milenic DE, Brady ED, Brechbiel MW: Antibody-targeted radiation cancer therapy. Nature Rev. Drug Discovery 3(6), 488–498 (2004).Detailed overview of the current state of radioimmunotherapy of cancer.
  Google Scholar
• 9  Kaminski MS, Tuck M, Estes J et al.:¹³¹I-tositumomab therapy as initial treatment for follicular lymphoma. N. Engl. J. Med.352(5), 441–449 (2005).
  Medline CASGoogle Scholar
• 10  Nicolaus RA: Melanins: Hermann, Paris 1968.
  Google Scholar
• 11  Borovansky J, Riley PA: The effect of divalent cations on Cloudman melanoma cells. Eur. J. Cancer Clin. Oncol.19(1), 91–99 (1983).
  Medline CASGoogle Scholar
• 12  Farmer PJ, Gidanian S, Shahandeh B, Di Bilio AJ, Tohidian N, Meyskens FL Jr: Melanin as a target for melanoma chemotherapy: pro-oxidant effect of oxygen and metals on melanoma viability. Pigment Cell Res.16(3), 273–279 (2003).
  Medline CASGoogle Scholar
• 13  Lewis JS, Laforest R, Buettner TL et al.: Copper-64-diacetyl-bis(N-4-methylthiosemicarbazone): an agent for radiotherapy. Proc. Natl Acad. Sci. USA98(3), 1206–1211 (2001).
  Medline CASGoogle Scholar
• 14  Link EM: Targeting melanoma with 211At/131I-methylene blue: preclinical and clinical experience. Hybridoma 18(1), 77–82 (1999).
  Google Scholar
• 15  Moins N, Papon J, Seguin H et al.: Synthesis, characterization and comparative biodistribution study of a new series of p-iodine-125 benzamides as potential melanoma imaging agents. Nucl. Med. Biol.28(7), 799–808 (2001).
  Medline CASGoogle Scholar
• 16  Bonafous J, Moins N, Moreau MF et al.: A Phase II clinical trial of N-(2-diethylaminoethyl)-2-iodobenzamide, a new specific melanoma imaging agent. Congress of the European Association of Nuclear Medicine. 25–29 August 2001, Napoli, Italy. Eur. J. Nucl. Med.28(8), 1001 (2001).
  Google Scholar
• 17  Moins N, D’Incan M, Bonafous J: et al.: 123I-N-(2-diethylaminoethyl)-2-iodobenzamide: a potential imaging agent for cutaneous melanoma staging. Eur. J. Nucl. Med. Mol.29(11), 1478–1484 (2002).
  Medline CASGoogle Scholar
• 18  Chehade F, De Labriolle-Vaylet C, Michelot J et al.: Distribution of I-BZA (N-2-diethylaminoethyl-4-iodobenzamide) in grafted melanoma and normal skin: a study by secondary ion mass spectroscopy (Noisy-le-grand). Cell. Mol. Biol.47(3), 529–534 (2001).
  Medline CASGoogle Scholar
• 19  Guerquin-Kern JL, Hillion F, Madelmont JC, Labarre P, Papon J, Croisy A: Ultra-structural cell distribution of the melanoma marker iodobenzamide: improved potentiality of SIMS imaging in life sciences. Biomed. Eng. Online 3(1), 10 (2004).
  Google Scholar
• 20  Dadachova E, Nosanchuk JD, Shi L et al.: Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a monoclonal antibody to melanin. Proc. Natl Acad. Sci. USA101, 14865–14870 (2004).Describes radioimmunotherapy of human melanoma when radioactivity is delivered to the lesions by monoclonal antibody to melanin.
  Medline CASGoogle Scholar
• 21  Rosas AL, Nosanchuk JD, Feldmesser M, Cox GM, McDade HC, Casadevall A: Synthesis of polymerized melanin by Cryptococcus neoformans in infected rodents. Infect. Immun.68(5), 2845–2853 (2000).
  Medline CASGoogle Scholar
• 22  Riley PA, Cooksey CJ, Johnson CI, Land EJ, Latter AM, Ramsden CA: Melanogenesis-targeted antimelanoma prodrug development: effect of side chain variations on the cytotoxicity of tyrosinase-generated ortho-quinones in a model screening system. Eur. J. Cancer33(1), 135–143 (1997).
  Medline CASGoogle Scholar
• 23  Yukitake J, Otake H, Inoue S, Wakamatsu K, Ito S: Comparison of in vivo antimelanoma effect of enantiomeric α-methyl- and α-ethyl-4-S-cysteaminylphenol. Melanoma Res.14(1), 115–120 (2004).
  Medline CASGoogle Scholar
• 24  Gili A, Thomas PD, Ota M, Jimbow K: Comparison of in vitro cytotoxicity of N-acetyl and N-propionyl derivatives of phenolic thioether amines in melanoma and neuroblastoma cells and the relationship to tyrosinase and tyrosine hydroxylase enzyme activity. Melanoma Res.10(1), 9–15 (2000).
  Medline CASGoogle Scholar
• 25  Lant NJ, McKeown P, Timoney MC, Kelland LR, Rogers PM, Robins DJ: Synthesis and antimelanoma activity of analogues of N-acetyl-4-S-cysteaminylphenol substituted with two methyl groups alpha to the nitrogen. Anticancer Drug Des.16(1), 49–55 (2001).
  Medline CASGoogle Scholar
• 26  Slominski A: Coming of age of melanogenesis-related proteins: Arch. Pathol. Lab. Med.126(7), 775–777 (2002).Description of the origins and functions of melanogenesis-related proteins.
  MedlineGoogle Scholar
• 27  Boyle JL, Haupt HM, Stern JB, Multhaupt HA: Tyrosinase expression in malignant melanoma, desmoplastic melanoma, and peripheral nerve tumors. Arch. Pathol. Lab. Med.126(7), 816–822 (2002).
  Medline CASGoogle Scholar
• 28  Sheffield MV, Yee H, Dorvault CC et al.: Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations. Am. J. Clin. Pathol.118(6), 930–936 (2002).
  MedlineGoogle Scholar
• 29  Miao Y, Whitener D, Feng W, Owen NK, Chen J, Quinn TP: Evaluation of the human melanoma targeting properties of radiolabeled α-melanocyte stimulating hormone peptide analogues. Bioconjug. Chem.4(6), 1177–1184 (2003).
  MedlineGoogle Scholar
• 30  Cheng Z, Chen J, Quinn TP, Jurisson SS: Radioiodination of rhenium cyclized α-melanocyte-stimulating hormone resulting in enhanced radioactivity localization and retention in melanoma. Cancer Res.64(4), 1411–1418 (2004).
  Medline CASGoogle Scholar
• 31  Miao Y, Owen NK, Fisher DR, Hoffman TJ, Quinn TP: Therapeutic efficacy of a 188Re-labeled α-melanocyte-stimulating hormone peptide analog in murine and human melanoma-bearing mouse models. J. Nucl. Med.46(1), 121–129 (2005).First attempt to treat melanoma in an animal model with a radiolabeled peptide.
  Medline CASGoogle Scholar
• 32  Rofstad EK, Mathiesen B, Galappathi K: Increased metastatic dissemination in human melanoma xenografts after subcurative radiation treatment: radiation-induced increase in fraction of hypoxic cells and hypoxia-induced upregulation of urokinase-type plasminogen activator receptor. Cancer Res.64(1), 13–18 (2004).
  Medline CASGoogle Scholar
• 33  Chin L: The genetics of malignant melanoma: lessons from mouse and man. Nature Rev. Cancer3(8), 559–570 (2003).
  Medline CASGoogle Scholar
• 34  Morilla-Grasa A: Animal models in uveal melanoma: establishment and research. Can. J. Ophthalmol.39(4), 433–440 (2004).
  MedlineGoogle Scholar
• 35  Behr TM, Behe M, Kluge G et al.: Nephrotoxicity versus antitumour efficacy in radiopeptide therapy: facts and myths about the Scylla and Charybdis. Eur. J. Nucl. Med. Mol. Imaging 29(2), 277–279 (2002).
  MedlineGoogle Scholar